Risk factors for DIC in paediatric APL: Insights from the CCLG‐APL 2016 study
To identify early risk factors for disseminated intravascular coagulation (DIC), particularly severe DIC (grade 4-5), in paediatric acute promyelocytic leukaemia (APL). One hundred and eighty-six paediatric APL patients enrolled in the Chinese Children Leukemia Group (CCLG)-APL 2016 study across 38 hospitals nationwide were grouped based on the occurrence and severity of DIC during induction therapy. DIC occurred in 52.2% of patients during induction therapy, with 7.5% developing grade 4-5 DIC. Significant differences were observed between the DIC and non-DIC groups in the proportion of patients with initial white blood cells (WBC) ≥5 × 10<sup>9</sup>/L, initial platelets (PLT) ≤26 × 10<sup>9</sup>/L and arsenic trioxide (ATO) use (p < 0.05). Multivariate analysis identified initial PLT ≤26 × 10<sup>9</sup>/L (p = 0.002, odds ratio [OR] = 2.679, 95% confidence interval [CI]: 1.438-4.992) as an independent risk factor, while induction therapy using realgar-indigo naturalis formula (RIF) was a protective factor (p = 0.030, OR = 0.465, 95% CI: 0.232-0.929). Further analysis revealed that Fms-like tyrosine kinase 3 (FLT3) mutation (p = 0.023, OR = 11.742, 95% CI: 1.405-98.149), initial PLT ≤26 × 10<sup>9</sup>/L (p = 0.017, OR = 13.784, 95% CI: 1.598-118.905) and initial bone marrow blasts ≥90% (p = 0.030, OR = 5.289, 95% CI: 1.178-23.744) were significant risk factors for grade 4-5 DIC. Initial WBC ≥5 × 10<sup>9</sup>/L and PLT ≤26 × 10<sup>9</sup>/L are associated with an increased risk of DIC, with PLT ≤26 × 10<sup>9</sup>/L as an independent risk factor. Compared with ATO, RIF is a protective factor during induction therapy. Additionally, FLT3 mutation, PLT ≤26 × 10<sup>9</sup>/L and initial bone marrow blasts ≥90% are independent risk factors for grade 4-5 DIC.
Authors
- Runming Jin
- Guoping Hao (ORCID: https://orcid.org/0000-0003-2023-3939)
- Jiaole Yu
- Ruidong Zhang (ORCID: https://orcid.org/0000-0003-3364-2352)
- Xin Tian (ORCID: https://orcid.org/0000-0001-9601-3751)
- Ying Wu (ORCID: https://orcid.org/0000-0002-5635-8090)
- Ansheng Liu
- Xiuli Ju (ORCID: https://orcid.org/0000-0001-5464-3106)
- Shaoyan Hu (ORCID: https://orcid.org/0000-0002-3386-6957)
- Yongjun Fang (ORCID: https://orcid.org/0000-0002-1081-6471)
- Linya Wang
- Pengli Huang
- Diying Shen (ORCID: https://orcid.org/0000-0002-2870-1154)
- Yaguang Peng
- Huyong Zheng (ORCID: https://orcid.org/0009-0006-5680-0295)
- Yuanyuan Zhang (ORCID: https://orcid.org/0000-0002-4142-3216)
- Jianxin Li (ORCID: https://orcid.org/0000-0002-7752-4000)
- Ning Liao (ORCID: https://orcid.org/0000-0002-1780-5652)
- Jia Fan (ORCID: https://orcid.org/0000-0001-5158-629X)
- Wei Lin (ORCID: https://orcid.org/0009-0006-5068-4502)
- Peijing Qi (ORCID: https://orcid.org/0000-0001-6926-4248)
- Qingyuan Xu
Institutions
- Capital Medical University (CN)
- Soochow University (CN)
- Nanjing Children's Hospital (CN)
- Kunming Children's Hospital (CN)
- Children's Hospital of Zhejiang University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Wuhan Union Hospital (CN)
- Xi’an Children’s Hospital (CN)
- Wuhan Children's Hospital (CN)
- Beijing Children’s Hospital (CN)
- Shanxi Provincial Children's Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1111/bjh.70211
- Primary Topic
- Retinoids in leukemia and cellular processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00